Susanta Roychoudhury Selected Research

Estrogens (Estrogen)

1/2017	Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance.
12/2013	Frequent alterations of MCPH1 and ATM are associated with primary breast carcinoma: clinical and prognostic implications.
10/2011	Frequent alterations of LOH11CR2A, PIG8 and CHEK1 genes at chromosomal 11q24.1-24.2 region in breast carcinoma: clinical and prognostic implications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susanta Roychoudhury Research Topics

Disease

41	Neoplasms (Cancer) 04/2024 - 01/2004
10	Squamous Cell Carcinoma of Head and Neck 01/2021 - 03/2006
9	Breast Neoplasms (Breast Cancer) 11/2022 - 01/2004
8	Carcinoma (Carcinomatosis) 11/2020 - 10/2006
6	Carcinogenesis 10/2023 - 11/2010
4	Lung Neoplasms (Lung Cancer) 10/2023 - 10/2019
4	Infections 06/2018 - 03/2015
4	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2017 - 08/2009
4	Colorectal Neoplasms (Colorectal Cancer) 06/2016 - 01/2011
3	Lymphatic Metastasis 10/2019 - 10/2011
3	Leukoplakia 11/2015 - 12/2005
3	Chromosomal Instability (Chromosome Stability) 01/2015 - 05/2011
3	Duodenal Ulcer (Curling's Ulcer) 03/2011 - 05/2006
3	Skin Neoplasms (Skin Cancer) 07/2008 - 10/2006
2	Ovarian Neoplasms (Ovarian Cancer) 09/2023 - 01/2017
2	Neoplasm Metastasis (Metastasis) 12/2022 - 10/2017
2	Mouth Neoplasms (Oral Cancer) 01/2021 - 03/2016
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2018 - 07/2015
2	Uterine Cervical Dysplasia 01/2018 - 07/2015
2	Chromosome Aberrations (Chromosome Abnormalities) 02/2015 - 07/2008
2	Keratosis 07/2008 - 10/2006
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Adenocarcinoma 01/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Triple Negative Breast Neoplasms 11/2020
1	Residual Neoplasm 08/2020
1	Adenocarcinoma of Lung 10/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2019
1	Head and Neck Neoplasms (Head and Neck Cancer) 04/2016
1	Inflammation (Inflammations) 07/2015
1	Colonic Neoplasms (Colon Cancer) 05/2015

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2007
6	MicroRNAs (MicroRNA)IBA 12/2022 - 02/2015
6	CateninsIBA 01/2021 - 01/2011
5	Codon (Codons)IBA 08/2009 - 09/2002
4	ArsenicIBA 11/2020 - 10/2006
4	RNA (Ribonucleic Acid)IBA 10/2019 - 01/2012
3	Transcription Factors (Transcription Factor)IBA 09/2023 - 11/2017
3	Messenger RNA (mRNA)IBA 11/2020 - 11/2010
3	Biomarkers (Surrogate Marker)IBA 10/2019 - 11/2015
3	DNA (Deoxyribonucleic Acid)IBA 10/2017 - 05/2015
3	Progesterone Receptors (Progesterone Receptor)IBA 01/2017 - 10/2011
3	Estrogens (Estrogen)FDA Link 01/2017 - 10/2011
3	Arginine (L-Arginine)FDA Link 08/2009 - 10/2006
2	Drinking WaterIBA 11/2020 - 10/2006
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2019 - 07/2015
2	AnthracyclinesIBA 03/2019 - 08/2018
2	Type I DNA Topoisomerases (Topoisomerase I)IBA 08/2018 - 05/2015
2	Anaphase-Promoting Complex-CyclosomeIBA 01/2015 - 01/2007
2	GastrinsIBA 03/2011 - 07/2009
2	Proline (L-Proline)FDA Link 08/2009 - 09/2002
2	arginylprolineIBA 10/2006 - 12/2005
2	Cyclin D1IBA 09/2004 - 01/2004
1	Peptides (Polypeptides)IBA 04/2024
1	XenobioticsIBA 10/2023
1	Oncogene Proteins (Oncogene Protein)IBA 09/2023
1	Mitochondrial DNA (mtDNA)IBA 09/2023
1	Cyclin-Dependent Kinase Inhibitor p57IBA 01/2023
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2023
1	Amyloid (Amyloid Fibrils)IBA 12/2022
1	Hormones (Hormone)IBA 11/2022
1	Imatinib Mesylate (Gleevec)FDA Link 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	mesoglycanIBA 01/2021
1	AcetoinIBA 01/2021
1	Amino Acids FDA Link 01/2021
1	CarbonIBA 01/2021
1	Dihydrotachysterol (AT 10)IBA 01/2021
1	PolymersIBA 01/2021
1	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 01/2021
1	Untranslated RNA (Noncoding RNA)IBA 01/2020
1	NogalamycinIBA 03/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 03/2019
1	Antineoplastic Agents (Antineoplastics)IBA 08/2018
1	1,2,5,8-tetrahydroxy anthraquinoneIBA 08/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018
1	Complement System Proteins (Complement)IBA 10/2017
1	Topoisomerase InhibitorsIBA 02/2017
1	lysophosphatidic acidIBA 01/2017
1	oncolipidsIBA 01/2017
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2017
1	Floxuridine (FUdR)FDA LinkGeneric 06/2016
1	Cisplatin (Platino)FDA LinkGeneric 04/2016
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 04/2016
1	Cadherins (E-Cadherin)IBA 04/2016
1	SurvivinIBA 04/2016
1	beta CateninIBA 01/2016
1	CarcinogensIBA 11/2015
1	Etoposide (VP 16)FDA LinkGeneric 07/2015
1	HLA-DQB1 antigen (HLA DQB1)IBA 07/2015
1	Topoisomerase II InhibitorsIBA 05/2015
1	trioctyl phosphine oxide (TOPO)IBA 05/2015
1	EnzymesIBA 05/2015
1	Virulence Factors (Pathogenicity Factors)IBA 03/2015
1	Fluorescein-5-isothiocyanate (FITC)IBA 02/2015

Therapy/Procedure

8	Drug Therapy (Chemotherapy) 10/2023 - 01/2013
7	Therapeutics 06/2023 - 01/2013
2	Neoadjuvant Therapy 01/2017 - 01/2013
1	Adjuvant Chemotherapy 08/2020
1	Aftercare (After-Treatment) 03/2019